ISPO

molecular targets for drug therapy

Selective Induction of cancer cell death by exploiting cell cycle checkpoints

CJ Li MD , YZ Li Md , AB Pardee PhD

Interference with cell cycle control mechanisms: phase-I study of a benzenedisulfonamide inhibiting cyclin E and cdk-2 phosphorylation

C Dittrich , H Dumez , H Calvert , AR Hanauske , M Ravic , M Faber , T van Houten , J Wanders , P Fumoleau

An anti-RAS cancer potential of PPI, an inhibitor specific for SRC family kinase: In vitro and in vivo studies

H He MD PhD , Y Hirokawa MD , A Levitzki PhD , H Maruta PhD

Targeting the CD22 receptor on human B-cell lymphomas with RNA damaging agents

DL Newton PhD , SM Mikulski MD , EA Sausville MD PhD , SM Rybak PhD

Chimeric oligonucleotides addressing two target sites of human telomerase are strong inhibitors of telomerase activity in U87 glioblastoma cells

E Matthes MD, C Lehmann, M Stulich, M von Janta-Lipinski PhD

Abnormal E-cadherin as basis for a novel gastric cancer therapy: functional analysis of a mutation-specific immunotoxin

KF Becker , J Mages , E Kremmer , QC Wang , I Pastan , H Höfler

Estradiol induces the assembly of ERΑ-p60src-p130Cas complex: modulation of anti-estrogen resistance in breast cancer cells

G Baj MD , L Moro PhD , A Arnulfo MD , M Proverbio PhD , A Vigone MD , G Tarone PhD , L Silengo MD PhD , N Surico MD , P Defilippi PhD